Abstract
INTRODUCTION
Hepatitis B virus (HBV) infection is a global public health problem [1] . HBV is a small encircled DNA virus belonging to the Hepadnaviridae family. HBV infection could cause either acute or chronic hepatitis, even leading to liver cirrhosis and hepatocellular carcinoma (HCC) [2] . A previous study reported that 2 billion people were infected with the HBV virus worldwide, and more than 350 million were chronic HBV carriers [3] . Additionally, over 600000 deaths have been triggered by HBV virus infection [4] . Although some clinical drugs, such as α-interferon and nucleoside analogs, could inhibit HBV replication to some extent for treatment of HBV infection, they could not induce persistent antivirus immune response and completely clear HBV in infected liver resulting from the existence of HBV covalently closed circular DNA and drug-resistant HBV mutants [5] [6] [7] . Due to the suboptimality and incompletion of the currently existing therapies for HBV infection [8] , it is urgently necessary to elucidate the mechanisms underlying HBV replication and to identify novel molecular targets for HBV therapy.
microRNAs (miRNAs) are a class of small noncoding RNAs of 18 to 25 nucleotides in length, which play crucial regulatory roles in various physiological and pathological processes, especially in tumorigenesis and cancer progression [9] . These small RNAs function as post-transcriptional regulators by imperfect base pairing with the 3'-untranslated region (3'-UTR), coding region or 5'-untranslated region (5'-UTR) of target mRNAs, and usually lead to translational repression or RNA degradation [10, 11] . In addition, miRNAs could also be used as a decoy interfering with the function of regulatory proteins [12] . For instance, miR-328 could interact with the RNA-binding protein hnRNP E2 independent of the miRNA's seed sequence and lead to release of CEBPA mRNA from hnRNP E2-mediated translational inhibition [12] . Another study elucidated that miRNAs can also target non-coding RNA and regulate the expression of itself in a feedback control manner, a novel regulatory mechanism of miRNAs [13] . miRNAs are closely related to the occurrence of cancer and serve as oncogenes or tumor suppressor genes involved in rich disordered pathways in cancers [14] . Up to now, abnormal expression of miRNAs has been detected in almost all types of cancers [15] .
Several studies have reported that miR-210, miR199a-3p and miR-125a-5p were involved in regulative process of HBV replication, by either directly binding to HBV transcripts or targeting crucial transcription factors participating in HBV gene replication and expression [16] [17] [18] . Moreover, a recent study indicated that epigenetically regulated miR-449a promoted HBV replication and gene expression by targeting cAMPresponsive element binding protein 5 to increase the expression of FXRα, a transcription factor facilitating HBV replication [19] .
The functional role of miR-29a varies in different cancers. For example, miR-29a was involved in tumorigenesis in acute myeloid leukemia and breast cancer as a tumor promotor [20, 21] . On the contrary, miR29a was implicated in lung cancer, cholangiocarcinoma and chronic lymphocytic leukemia acting as a tumor suppressor [22, 23] . Additionally, miR-29a exerts important roles in liver diseases. For instance, a study stated that miR-29a could regulate hepatoma cell migration mediated by HBx through directly targeting PTEN in HBV-related HCC [24] . miR-29a was shown to have a protective role against acute liver injury in a mouse model of obstructive jaundice [25] . miR-29a has also been shown to induce apoptosis of LX-2 cells and lead to the reversion of liver fibrosis in mice [26] .
Furthermore, miR-29a was found to be up-regulated in the HCC cell line HepG2.2.15 with HBV infection [27] . [28] demonstrated that the cellular transcription modulator, SWI/SNF-related matrixassociated actin-dependent regulator of chromatin subfamily E member 1 (SMARCE1), could repress HBV replication through binding to the core promoter of HBV. The expression of miR-29a was extensively investigated and well confirmed in many cancers, however, the functional role of miR-29a in HBV expression and replication regulation in HCC is still not clear. Here, we illustrate the underlying molecular mechanism of miR-29a in HBV replication and expression. , and β-actin served as the internal control. The primer sequences were as follows: for miR-29a 5'-ACAGGATATCGCATTGTTGG-3' (forward) and 5'-TATACCACATGCAATTCAG-3' (reverse); for SMARCE1 5'-CGGCTTATCTGGTGGCTTT-3' (forward) and 5'-GGAGGGTCGGACATCAACAA-3' (reverse); for U6 5'-CTCGCTTCGGCAGCACA-3' (forward) and 5'-AACGCTTCACGAATTTGCGT-3' (reverse); for β-actin 5'-TGAGAGGGAAATCGTGCGTGAC-3' (forward) and 5'-AAGAAGGAAGGCTGGAAAAGAG-3' (reverse). The relative expression of RNAs was calculated and normalized using the ∆∆Ct method, relative to the control gene. Each test was performed in triplicate.
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MATERIALS AND METHODS
Cell culture and transfection
Western blot analysis
Anti-SMARCE1 (Bethyl, Montgomery, TX, United States) and anti-β-actin (Sigma-Aldrich, St Louis, MO, United States) antibodies were used as monoclonal rabbit antibodies. Cells were harvested and total proteins were isolated with RIPA reagents (Thermo Scientific, Rockford, IL, United States) following the manufacturer's instructions. Subsequently, protein concentrations were quantified by using the BCA protein assay kit (Thermo Scientific). Western blot analysis was then performed following the previously described protocol [29] . The protein bands were visualized and quantified using the ImageQuant software (Molecular Dynamics, Sunnyvale, CA, United States).
HBV replication and gene expression analysis
HBV replicative intermediates from intracellular core particles were extracted from hepatoma cell lines and detected by Southern blotting, according to the previously published protocols [30] . HBV DNA was extracted using the Column Viral DNAout kit (TIANDZ, Beijing, China) following the manufacturer's protocol, and quantified by real-time PCR as described previously [30] . The levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were determined using enzyme-linked immunosorbent assay (ELISA) kits (Kehua Biotech, Shanghai, China).
Cell viability assays
HepG2.2.15 cells transfected with miR-29a mimics or anti-miR-29a were cultured for 48 h, and then cell viability was determined using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan).
Plasmid construction
The SMARCE1 expression construct was generated by PCR amplification of SMARCE1 from HepG2 cDNA using the following primers: forward, 5'-GTACGAATTC CACCATGTCAAAAAGACCATCTTATGC-3'; reverse, 3'-GAATAAGTGTTGCCTTGTTTTGTGCTCGAGACTG-5'. The fragment was cloned into the pcDNA3.1 expression vector using the EcoR I and Xho I restriction sites in the multiple cloning site and sequence verified. For 3'-UTR reporter plasmids, the 3'-UTR of SMARCE1 containing the predicted miR-29a target site was amplified by the primers (forward, 5'-GTACGCTAGCGGC TCAGTCAGTCACCTTTC-3'; reverse, 3'-ATCTGGTCTCG GGTGGAAACTCGAGACTG-5'), and then cloned into a pGL3 reporter vector using the Nhe I and Xho I restriction sites in the multiple cloning site.
Luciferase reporter assays
HEK293T cells were co-transfected with 50 nmol/L miR-29a mimics or control miRNA and 0.4 µg of pGL3 reporter vectors containing wild-type or mutant 3'-UTR of SMARCE1 using Lipofectamine 2000 (Invitrogen). pRL-CMV (Promega) was co-transfected as a normalization control. Luciferase activities were measured 48 h post-transfection using the DualLuciferase Reporter Assay System (Promega) according to the manufacturer's protocol.
Statistical analysis
All data were presented as mean ± SD and analyzed using SPSS 19.0 software (IBM Corp, Armonk, NY, United States). The statistical significance was calculated with the Student's t-test or one-way ANOVA. A P value of less than 0.05 was considered statistically significant.
RESULTS
miR-29a is up-regulated and SMARCE1 is downregulated in HBV-infected HepG2.2.15 cells
The levels of miR-29a and SMARCE1 in HepG2 (NC) 29a promoted HBV replication and expression in HepG2.2.15 cells.
miR-29a has no effect on HepG2.2.15 cell viability
To further investigate whether miR-29a transfection had effects on host cells, CCK-8 was used to detect the cell viability of HepG2.2.15 cells transfected with miR-control, miR-29a mimics or anti-miR-29a. The CCK-8 assay showed that miR-29a mimics, as well as anti-miR-29a, had no significant effect on HepG2.2.15 cell viability compared to respective controls ( Figure  3A and B). These results indicated that miR-29a transfection did not damage the host cells.
SMARCE1 suppresses HBV replication and expression in HepG2.2.15 cells
To confirm the effect of SMARCE1 on HBV replication and expression, HepG2.2.15 cells were transfected with pcDNA-control, pcDNA-SMARCE1, si-control or si-SMARCE1, respectively. Western blot analysis indicated that SMARCE1 was overexpressed or down-regulated after pcDNA-SMARCE1 or si-SMARCE1 transfection ( Figure 4A ). The effect of SMARCE1 on HBV DNA replication was measured by quantitative (q)PCR and Southern blot, while the expression levels of HBsAg and HBeAg were detected by ELISA.
The results of qPCR and Southern blot analysis indicated that SMARCE1 overexpression significantly reduced the HBV DNA replication ( Figure 4B and E 
miR-29a promotes HBV replication and expression in HepG2.2.15 cells
To examine whether miR-29a affected HBV replication and expression, HepG2.2.15 cells were transfected with miR-control, miR-29a mimics or anti-miR-29a, respectively. The influence of miR-29a on HBV DNA replication was measured by quantitative PCR (qPCR) and Southern blot, while the expression levels of HBsAg and HBeAg were detected by ELISA. The qPCR and Southern blot analysis indicated that the overexpression of miR-29a significantly increased the HBV DNA replication, while the endogenous miR-29a inhibition by anti-miR-29a obviously decreased its replication compared with the controls (Figure 2A and  B) . Moreover, ELISA assay demonstrated that miR-29a overexpression significantly elevated the expression levels of HBsAg and HBeAg, while the endogenous miR-29a inhibition by anti-miR-29a markedly reduced their expression levels compared with the controls (Figure 2C ). Together, these results implied that miR- 
Figure 4 Effect of SMARCE1 on hepatitis B virus replication and expression (n = 3).
A: HepG2.2.15 cells were transfected with pcDNA-control, pcDNA-SMARCE1, si-control, or si-SMARCE1 for 24 h; B and E: Western blotting was performed to detect the level of SMARCE1 after pcDNA-SMARCE1 or si-SMARCE1 transfection; C and D: qPCR and Southern blotting analysis showed that SMARCE1 overexpression significantly reduced the HBV DNA replication and SMARCE1 knockdown significantly increased the HBV DNA replication; F and G: ELISA assay showed that SMARCE1 overexpression significantly decreased the levels of HBsAg and HBeAg; H and I: Endogenous SMARCE1 inhibition by si-SMARCE1 significantly promoted the levels of HBsAg and HBeAg.
a P < 0.05 vs controls. Data represent the mean ± SD. Figure 4C and D) . Moreover, ELISA assay revealed that SMARCE1 overexpression significantly decreased the expression levels of HBsAg and HBeAg ( Figure 4F and G) , while the si-SMARCE1 knockdown notably enhanced their expression levels ( Figure  4H and I) . These results indicated that SMARCE1 suppressed HBV replication and expression.
SMARCE1 is directly targeted by miR-29a in HepG2.2.15 cells
Considering that the expression and function of miR29a and SMARCE1 were inverse and that miRNAs play their roles by targeting specific target, we speculated that miR-29a might promote HBV replication and expression by regulating the expression of SMARCE1. Therefore, miRNA target analysis tools TargetScan and PicTar were used to predict the potential targets of miR-29a. The results showed that 3'-UTR of SMARCE1 contained the binding sequence of miR-29a ( Figure  5A ). Then, dual-luciferase reporter assay was used to confirm that SMARCE1 was directly targeted by miR29a. Results showed that miR-29a overexpression significantly decreased the luciferase activity of the wild-type reporter gene (WT), but not the mutant reporter gene (MUT) ( Figure 5B ).
To further determine whether miR-29a can indeed repress the expression of SMARCE1, HepG2.2.15 cells were transfected with miR-control, miR-29a mimics or anti-miR-29a, and then the mRNA and protein levels of SMARCE1 were detected by qRT-PCR and western blot, respectively. Results displayed that miR-29a overexpression significantly lowered the protein level of SMARCE1 and miR-29a inhibition significantly promoted the protein level of SMARCE1 ( Figure 5D and E), and that miR-29a overexpression or inhibition had no obvious effects on the mRNA level of SMARCE1, which indicated that miR-29a suppressed SMARCE1 expression at the post-transcriptional level. Taken together, these results illuminated that miR-29a directly targeted 3'-UTR of SMARCE1 to regulate its expression in HepG2.2.15 cells. 
miR-29a promotes HBV replication and expression by regulating SMARCE1
To clarify whether miR-29a promoted HBV replication and expression through regulating SMARCE1, HepG2.2.15 cells were transfected with miR-control or miR-29a mimics or co-transfected miR-29a mimics with pcDNA-control or pcDNA-SMARCE1. The results showed that miR-29a overexpression strikingly augmented HBV replication, whereas co-transfection of pcDNA-SMARCE1 attenuated the effect of miR-29a on HepG2.2.15 cells (Figure 6A and B) . As shown in Figure 6C and D, miR-29a overexpression evidently enhanced HBsAg and HBeAg expression, whereas cotransfection of pcDNA-SMARCE1 significantly restored the effect of miR-29a on HBsAg and HBeAg expression in HepG2.2.15 cells. These results demonstrated that miR-29a promoted HBV replication and expression through targeting SMARCE1 in HepG2.2.15 cells.
DISCUSSION
To improve the treatment of HBV infection, new therapeutic targets and strategies must be identified and developed. Recently, studies on miRNAs have provided novel insights into the potential cure of HBV infection. Moreover, a growing number of works have revealed that miRNAs play critical roles in the HBV replication and expression processes [16] [17] [18] . However, their underlying molecular mechanisms remain to be further elucidated.
In our study, we explored the role of miR-29a in the regulation of HBV replication and expression. We found that the expression of miR-29a was significantly up-regulated in the HBV-infected HCC cell line HepG2.2.15. Overexpression of miR-29a increased the HBV replication and expression, while miR-29a knockdown decreased the replication and expression of HBV. These results suggested that miR-29a could be a promising diagnostic biomarker and therapeutic target for HBV infection.
Recent studies indicated that the host cellular miRNAs could regulate the HBV replication and expression by directly targeting HBV transcripts or indirectly targeting HBV transcription regulatory factors 
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This study is well designed and the manuscript is well written. needed for HBV transcription [31] . For instance, Zhang et al [17] showed that miR-199a-3p targeted the coding regions of HBsAg and miR-210 specifically bound to the preS1 region of HBV, and they were further confirmed to inhibit HBV replication and expression through directly targeting HBV RNA. Potenza et al [16] also found that miR-125a-5p interacted with the RNA encoded by HBV surface antigen, eventually reducing the secretion of HBsAg. Wu et al [32] reported that miR-7, miR-196, miR-433 and miR-511 might directly target HBV DNA polymerase and surface antigen genes, and miR-205 and miR-345 could target HBx and the pre-core gene, respectively. In addition, Wang et al [33] demonstrated that miR-155 could promote HBV enhancer II activity in a dose-dependent manner by directly targeting CEBP-β. Zhang et al [30] confirmed that miR-1 improved farnesoid X receptor alpha (FXRA) expression and enhanced HBV core promoter transcription activity. Furthermore, HCC cell proliferation and cell cycle arrest modulated by miR-29a may also influence HBV replication and gene expression [34] . In the present study, we found that miR-29a was up-regulated in the HCC cell line HepG2.2.15, consistent with findings from a previous study [27] . However, the possible influencing mechanism of miR-29a on HBV replication and expression was not illustrated. Our study enriches the miRNAs and HBV-host interaction theory.
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SMARCE1 is a member of the SWI/SNF family of chromatin-remodeling complexes, playing key roles in transcriptional control. A previous study reported that SWI/SNF was recruited to neuronal genes by the CoREST corepressor, interacting with the DNA binding repressor [35] . In another study, the potential tumor suppressor, prohibitin, was implied to recruit SWI/SNF to a particular E2F-dependent promoter and inhibit E2F-mediated transcription [36] . However, the role of SMARCE1 in HBV replication and expression was largely unknown. In the present study, we found that overexpression of SMARCE1 decreased the HBV replication and expression, while inhibition of SMARCE1 increased the HBV replication and expression. SMARCE1 repressed HBV replication through binding to the mutant core promoter of HBV in HepG2 cells [28] , which also revealed that SMARCE1 could repress HBV replication; however, the functional mechanism of SMARCE1 involved in HBV replication may be different from that observed in our study. Furthermore, a dual-luciferase assay was performed and SMARCE1 was verified to be a target of miR-29a and was regulated by miR-29a at the protein levels. Restoration of SMARCE1 expression by pcDNA-SMARCE1 recuperated the promoting effect of miR-29a on the HBV replication and expression. These findings suggested that miR-29a promoted HBV replication and expression by targeted inhibition of SMARCE1 expression, providing a theoretical foundation for the clinical application of miRNAs in therapy of HBV infection.
In summary, the expression of miR-29 was upregulated in the HCC cell line HepG2.2.15 infected with HBV. Aberrantly expressed miR-29a affected
